IGC Pharma
30 hedge funds and large institutions have $1.36M invested in IGC Pharma in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.71% less ownership
Funds ownership: 5.92% → 5.2% (-0.71%)
14% less funds holding
Funds holding: 35 → 30 (-5)
40% less capital invested
Capital invested by funds: $2.27M → $1.36M (-$907K)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.3K |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.86K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$125K |
| 2 |
Renaissance Technologies
New York
|
-$107K |
| 3 |
VF
Virtu Financial
New York
|
-$37K |
| 4 |
HF
HRT Financial
New York
|
-$25K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$14.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FFA
26
Farther Finance Advisors
San Francisco,
California
| $28 | – | – | – |
|
|
HC
27
Hurley Capital
New York
| $28 | – | – | – |
|
|
RFP
28
Root Financial Partners
Encinitas,
California
| $28 | +$36 | +100 | New |
|
|
DFA
29
DHJJ Financial Advisors
Naperville,
Illinois
| $23 | – | – | – |
|
|
TCM
30
Triumph Capital Management
Denver,
Colorado
| $1 | +$1 | +2 | New |
|
|
VF
31
Virtu Financial
New York
| – | -$37K | -89,546 | Closed |
|
|
HF
32
HRT Financial
New York
| – | -$25K | -60,258 | Closed |
|
|
TSS
33
Two Sigma Securities
New York
| – | -$14.6K | -35,028 | Closed |
|
|
GCP
34
GSA Capital Partners
London,
United Kingdom
| – | -$12K | -27,821 | Closed |
|
|
BBA
35
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$3.6K | -13,961 | Closed |
|
|
TDC
36
Thompson Davis & Co
Richmond,
Virginia
| – | -$4.17K | -10,000 | Closed |
|
37
Simplex Trading
Chicago,
Illinois
| – | -$76 | -212 | Closed |
|
|
EWM
38
Evermay Wealth Management
Arlington,
Virginia
| – | -$13 | -30 | Closed |
|
39
Fidelity Investments
Boston,
Massachusetts
| – | -$2 | -5 | Closed |
|
IGC Hedge Fund Activity: Q4 2025 in Review
30 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2025, worth a combined $1.36M — down 40% from $2.27M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IGC and 5 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Susquehanna International Group, adding an estimated $50.3K. The largest seller was Citadel Advisors, cutting an estimated $125K.
- 30 institutional investors held IGC Pharma (IGC) as of Q4 2025, down from 35 in Q3 2025.
- Funds reported $1.36M of IGC Pharma stock for Q4 2025, down 40% quarter-over-quarter.
- 5 funds opened new IGC Pharma positions in Q4 2025 and 9 closed out, a net change of -4 holders.
- The largest IGC Pharma buyer in Q4 2025 was Susquehanna International Group, an estimated $50.3K added.
- The largest IGC Pharma seller in Q4 2025 was Citadel Advisors, an estimated $125K sold.
Based on aggregated 13F filings for Q4 2025.